# Bahria University

Organization · id `cardio:org-bahria-university` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ROR record 02v8d7770](<https://ror.org/02v8d7770>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. Matched to ROR record 02v8d7770 by an exact name.

## The registry's words

- Sponsor name: Bahria University
- Sponsor class: OTHER
- ROR name: Bahria University

## Connected pages

- Sponsors: Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes (`cardio:ct-nct06759922`)
- Sponsors: Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol (`cardio:ct-nct07255820`)
- Sponsors: Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (`cardio:ct-nct07452913`)

## Provenance

Content hash: f85325e35ec003198e2778779977433dab4a482c055661c5bd78a5fa49750336
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
